Is Adlai Nortye Ltd. (NASDAQ:ANL) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Adlai Nortye Ltd. at current levels.
Five shots on goal in oncology, two with genuine blockbuster geometry, priced like the market still thinks it's one molecule.
Where ANL is headed
Adlai Nortye spent most of its public life being mistaken for a one-asset story. That story was AN0025, the EP4 antagonist, and the market priced it accordingly when the pivotal readouts in rectal cancer slipped and questions piled up about the immune-oncology combination data. Sitting here in mid-2026 at $11 with a $708M market cap, what's actually on the table is a five-program oncology pipeline where the EP4 asset has become the LEAST interesting bet. AN9025, the oral pan-RAS(ON) inhibitor, is the one to watch. The RAS-mutant space has shifted enormously since Mirati's KRAS franchise sold to Bristol and Revolution Medicines validated the pan-RAS thesis with RMC-6236 readouts that rerated the entire category. An oral, broad-spectrum RAS(ON) inhibitor competing in pancreatic, lung, and colorectal adenocarcinoma is not a niche shot. It's a swing at a $15-20B addressable market where every clean Phase 1 dose-escalation curve gets paid.
Read the full Compass Direction on ANL
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $10.84).
See the full ANL analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Adlai Nortye Ltd. (NASDAQ:ANL) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Adlai Nortye Ltd. at current levels. Five shots on goal in oncology, two with genuine blockbuster geometry, priced like the market still thinks it's one molecule.
What is ANL's Compass Score?
Adlai Nortye Ltd. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for ANL?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ANL page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.